Brown-Forman (BF.B, Financial) was highlighted in the Fundsmith 2024 Q4 letter as facing challenges from reduced consumption levels post-pandemic and potential impacts from weight loss drugs. Fundsmith LLP remains committed to holding Brown-Forman, citing its strong brand portfolio and the benefits of family control in strategic decision-making. The focus on premium spirits is seen as a potential buffer against industry headwinds.
"Brown-Forman... is probably seeing early signs of the adverse impact of weight loss drugs. We sold our Diageo stake during the year... but retaining Brown-Forman keeps a foothold in what has long been a sector with good business characteristics." — Fundsmith LLP, Fundsmith 2024 Q4 Fund Letter
Read full letter at gurufocus Fundsmith 2024 Q4 page.